FY2024 Earnings Estimate for Trevena Issued By HC Wainwright

Trevena, Inc. (NASDAQ:TRVN) – Research analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Trevena in a research note issued on Thursday, November 14th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will earn ($23.04) per share for the year, up from their prior forecast of ($32.25). HC Wainwright currently has a “Neutral” rating and a $5.00 target price on the stock. The consensus estimate for Trevena’s current full-year earnings is ($23.04) per share. HC Wainwright also issued estimates for Trevena’s Q4 2024 earnings at ($2.50) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.31) EPS.

Separately, StockNews.com started coverage on shares of Trevena in a report on Tuesday. They set a “sell” rating on the stock.

Trevena Trading Up 1.2 %

Shares of TRVN stock opened at $1.70 on Monday. The firm’s 50 day moving average is $2.86 and its 200 day moving average is $5.45. The stock has a market capitalization of $1.46 million, a P/E ratio of -0.04 and a beta of 1.08. Trevena has a 12 month low of $1.13 and a 12 month high of $19.23.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The business had revenue of $0.28 million for the quarter.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.